In this Supplement
Global thought leaders discuss the ELUVIA DES IMPERIAL Trial results and its influence on treatment decisions
Sustained drug-release in the SFA drives superior results.
By William A. Gray, MD; Additional commentary by Prof. Stefan Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA, FSIR
A multidisciplinary panel of PAD experts discuss the impact on patient care and the health care system and how these results may shift current treatment algorithms.
With Michael R. Jaff, DO; Gary M. Ansel, MD, FACC; William A. Gray, MD; Steve Henao, MD, FACC, FACS; and Robert A. Lookstein, MD
Two vascular experts share their reactions to hearing the results of the first head-to-head peripheral DES trial.